Open AccessDevelopment and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40
Author(s) -
Dong-Shan Yu,
Tian-Hao Weng,
Lei Shen,
Xiaoxin Wu,
Chen-Yu Hu,
Frederick X.C. Wang,
Zhigang Wu,
Haibo Wu,
Nanping Wu,
Lanjuan Li,
HangPing Yao
Publication year - 2018
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000494530
Subject(s) - ebolavirus , ebola virus , virology , monoclonal antibody , vp40 , antibody , glycoprotein , western blot , epitope , biology , virus , microbiology and biotechnology , immunology , biochemistry , gene
Monoclonal antibodies (mAbs) are presently the most promising treatment against Ebola virus disease (EVD), and cocktail of two or more antibodies likely confers protection through complementary mechanisms. Zaire Ebolavirus (EBOV) glycoprotein (GP) and viral protein 40 (VP40) are targets for designing neutralizing antibodies. Currently, the antiviral therapeutics of mAb-cocktails are still limited solely to anti-GP antibodiesthere is no Abs cocktail against Zaire EBOV GP and VP40, which both have important interactions with host cellular membrane.